Immunophotonics, Inc.

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2/3
STING and inflammasome pathwaysPolysaccharide
Non-Small Cell Lung CancerColorectal Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2033 (1)
December 2033 (1)
N-dihydrogalactochitosanPhase 2/3Colorectal Cancer (CRC), Colon Cancer Liver Metastases, Rectal Cancer, Rectal Cancer With Liver Metastases …
Est. primary completion 2033-12 · NCT07321847 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.